These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32857184)

  • 21. Molecular Risk Stratification in Aggressive B-Cell Lymphomas.
    Frosch ZAK; Landsburg DJ
    J Clin Oncol; 2020 Jun; 38(18):2014-2017. PubMed ID: 32243222
    [No Abstract]   [Full Text] [Related]  

  • 22. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
    Patte C; Auperin A; Michon J; Behrendt H; Leverger G; Frappaz D; Lutz P; Coze C; Perel Y; Raphaël M; Terrier-Lacombe MJ;
    Blood; 2001 Jun; 97(11):3370-9. PubMed ID: 11369626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
    Eyre TA; Martinez-Calle N; Hildyard C; Eyre DW; Plaschkes H; Griffith J; Wolf J; Fields PA; Gunawan A; Oliver R; Booth S; McMillan A; Fox CP; Bishton M; Collins GP; Hatton CSR
    Br J Haematol; 2019 Aug; 186(4):e94-e98. PubMed ID: 31020646
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
    Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
    Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
    Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
    Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
    Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay.
    Ta R; Santini C; Gou P; Lee G; Tai YC; O'Brien C; Fontecha M; Grant C; Bacon L; Finn S; Vandenberghe E; Quinn F; Dua R; Flavin R
    J Mol Diagn; 2021 Mar; 23(3):323-340. PubMed ID: 33385586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Xu-Monette ZY; Dabaja BS; Wang X; Tu M; Manyam GC; Tzankov A; Xia Y; Zhang L; Sun R; Visco C; Dybkaer K; Yin L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Zhao X; Winter JN; Piris MA; McDonnell TJ; Miranda RN; Li Y; Medeiros LJ; Young KH
    Mod Pathol; 2015 Dec; 28(12):1555-73. PubMed ID: 26541272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy.
    Schmitz C; Rekowski J; Müller SP; Farsijani N; Hertenstein B; Franzius C; von Verschuer U; La Rosée P; Freesmeyer M; Wilop S; Krohn T; Raghavachar A; Ganser A; Bengel FM; Prange-Krex G; Kroschinsky F; Kotzerke J; Giagounidis A; Dührsen U; Hüttmann A
    Cancer Med; 2020 Nov; 9(22):8386-8396. PubMed ID: 32926763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.
    Cherng HJ; Sargent RL; Nasta SD; Svoboda J; Schuster SJ; Mato AR; Schrank-Hacker A; Morrissette JJD; Landsburg DJ
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):673-678. PubMed ID: 30033208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.
    Mitobe M; Kawamoto K; Suzuki T; Suwabe T; Shibasaki Y; Masuko M; Inoue K; Miyoshi H; Ohshima K; Sone H; Takizawa J
    J Clin Exp Hematop; 2021 Mar; 61(1):42-47. PubMed ID: 33551436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.
    Sarkozy C; Morschhauser F; Dubois S; Molina T; Michot JM; Cullières-Dartigues P; Suttle B; Karlin L; Le Gouill S; Picquenot JM; Dubois R; Tilly H; Herbaux C; Jardin F; Salles G; Ribrag V
    Clin Cancer Res; 2020 Jul; 26(13):3145-3153. PubMed ID: 32122924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of durvalumab with R-CHOP or R
    Nowakowski GS; Willenbacher W; Greil R; Larsen TS; Patel K; Jäger U; Manges RF; Trümper L; Everaus H; Kalakonda N; Brown P; Jørgensen JM; Cunningham D; Dell'Aringa J; Fox B; Rubio ND; Kilavuz N; Casadebaig ML; Manzke O; Munoz J
    Int J Hematol; 2022 Feb; 115(2):222-232. PubMed ID: 34797531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.
    Hohloch K; Altmann B; Pfreundschuh M; Loeffler M; Schmitz N; Zettl F; Ziepert M; Trümper L
    Br J Haematol; 2018 Jan; 180(2):236-245. PubMed ID: 29193018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.
    Ibrahim EM; Refat S; El-Ashwah S; Fahmi MW; Ibrahiem AT
    J Egypt Natl Canc Inst; 2023 May; 35(1):12. PubMed ID: 37150782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Johnson NA; Slack GW; Savage KJ; Connors JM; Ben-Neriah S; Rogic S; Scott DW; Tan KL; Steidl C; Sehn LH; Chan WC; Iqbal J; Meyer PN; Lenz G; Wright G; Rimsza LM; Valentino C; Brunhoeber P; Grogan TM; Braziel RM; Cook JR; Tubbs RR; Weisenburger DD; Campo E; Rosenwald A; Ott G; Delabie J; Holcroft C; Jaffe ES; Staudt LM; Gascoyne RD
    J Clin Oncol; 2012 Oct; 30(28):3452-9. PubMed ID: 22851565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
    Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
    Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.